<DOC>
	<DOCNO>NCT00146224</DOCNO>
	<brief_summary>The purpose study evaluate whether efficacy Epoetin alfa DT equivalent Epoetin alfa RB treatment anemia patient CKD receive hemodialysis</brief_summary>
	<brief_title>Efficacy Epoetin Alfa Deep Tank Treatment Anemia Patients With Chronic Kidney Disease Receiving Hemodialysis</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Diagnosis CKD receive hemodialysis great equal 3 month randomization Mean HB level 10 13 g/dL ( inclusive ) ( mean 2 value draw least 3 day apart screen period ) Currently receive stable dose Epoetin alfa RB ( i.e. , EPOGEN® PROCRIT® ) least 6 week prior randomization . Stable define : less equal 25 % change dose 6 week , frequency route administration 1 miss withhold dose two threeweek period randomization Exclusion Criteria : Uncontrolled hypertension , define predialysis systolic BP great 180 and/or diastolic BP great 110 screening period Known history severe hyperparathyroidism ( PTH Greater 1500 pg/ml within 3 month prior enrollment ) Currently receive immunosuppressive therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>anemia</keyword>
	<keyword>chronic kidney disease , CKD</keyword>
	<keyword>hemodialysis</keyword>
	<keyword>epoetin</keyword>
	<keyword>Epogen®</keyword>
</DOC>